However, the prevalence of such antibodies appears to be low in MS patients, as three recent studies indicate that Neurofascin is not the dominant target of antibodies in MS (Devaux et al., 2012; Elliott et al., 2012; Kawamura et al., 2013). The gene discussed is NFASC; the disease is myeloid sarcoma.